Table 1.

Challenges associated with applying immunotherapy to T-cell malignancies.

Immunosuppression	Targeting T-cell malignancies is more likely to lead to profound immunosuppression than targeting other malignancies.
Fratricide	CAR-T cells may also express the antigen they themselves are targeting, leading to the failure of proliferation or death of the CAR-T cells.
Graft versus Host Disease	The risk of multisystem organ disease due to self-directed donor T-cells.
Disease Heterogeneity	Identifying uniform targets in T-ALL is challenging because of the relative paucity of common markers between T-ALL samples.
Immunotherapy Toxicities	Known toxicities due to immunotherapy, such as CRS and neurotoxicity, may be more pronounced in T-cell malignancies because of higher disease burden.
Autologous versus Allogeneic Products	Targeting T-cell malignancies may necessitate the use of allogeneic products which are more readily available for quicker use but carry an increased risk of GVHD.

CAR-T: chimeric antigen receptor T-cell; T-ALL: T-cell Acute Lymphoblastic Leukemia;